Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 59Cholangiocarcinoma 19Carcinoma, Renal Cell 16Biliary Tract Neoplasms 11Stomach Neoplasms 9Thyroid Neoplasms 8Endometrial Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 7Melanoma 6Uterine Cervical Neoplasms 5Thyroid Carcinoma, Anaplastic 5Neuroendocrine Tumors 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Ovarian Neoplasms 4Liver Neoplasms 4Thyroid Cancer, Papillary 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Cirrhosis, Familial, with Pulmonary Hypertension 3Brain Neoplasms 3Advanced Biliary Tract Cancer 3Adenocarcinoma, Follicular 3Vulvar Neoplasms 2Uveal Melanoma 2Triple Negative Breast Neoplasms 2Thymoma 2Solid Tumors 2

Interventions

Cisplatin 66Paclitaxel 43Radiotherapy 39Carboplatin 29Fluorouracil 27Drug Therapy 20Irinotecan 16toripalimab 15pembrolizumab 15tislelizumab 14camrelizumab 13sintilimab 12Radiotherapy, Intensity-Modulated 11Albumin-Bound Paclitaxel 11S 1 (combination) 10Capecitabine 10130-nm albumin-bound paclitaxel 10apatinib 9Radiation 9Oxaliplatin 9Neoadjuvant Therapy 9Esophagectomy 9Docetaxel 9nimotuzumab 8TP protocol 8Cetuximab 8anlotinib 7Nivolumab 7nedaplatin 6Taxes 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Squamous Cell Carcinoma × lenvatinib × Clear all
NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡